Wuhan Hvsen Biotechnology Co Ltd (300871) — Cash Flow Reinvestment Rate
Wuhan Hvsen Biotechnology Co Ltd (300871) has a Cash Flow Reinvestment Rate of 0.32x as of September 2025, reinvesting CN¥18.73 Million (capex CN¥18.73 Million ) from operating cash flow of CN¥59.06 Million. Check Wuhan Hvsen Biotechnology Co Ltd earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Wuhan Hvsen Biotechnology Co Ltd Cash Flow Reinvestment Rate (2016–2025)
Historical reinvestment intensity for Wuhan Hvsen Biotechnology Co Ltd across 10 annual periods. Explore 300871 cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Reinvestment Rate for Wuhan Hvsen Biotechnology Co Ltd (2016–2025)
Year-by-year capital reinvestment analysis for Wuhan Hvsen Biotechnology Co Ltd. For live market cap and broader valuation context, see 300871 company net worth.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.58x | CN¥138.60 Million | CN¥238.45 Million | CN¥96.92 Million | ▼ -91.2% |
| 2024 | 6.58x | CN¥286.61 Million | CN¥43.53 Million | CN¥194.43 Million | ▲ +115.0% |
| 2023 | 3.06x | CN¥284.62 Million | CN¥92.92 Million | CN¥184.31 Million | ▼ -61.0% |
| 2022 | 7.85x | CN¥758.87 Million | CN¥96.68 Million | CN¥428.87 Million | ▲ +21.0% |
| 2021 | 6.49x | CN¥1.01 Billion | CN¥155.72 Million | CN¥600.12 Million | ▼ -53.2% |
| 2020 | 13.87x | CN¥670.84 Million | CN¥48.35 Million | CN¥230.84 Million | ▲ +159.3% |
| 2019 | 5.35x | CN¥563.06 Million | CN¥105.24 Million | CN¥123.06 Million | ▼ -76.2% |
| 2018 | 22.47x | CN¥474.05 Million | CN¥21.10 Million | CN¥34.05 Million | ▲ +264.7% |
| 2017 | 6.16x | CN¥496.40 Million | CN¥80.56 Million | CN¥56.40 Million | ▲ +1222.0% |
| 2016 | 0.47x | CN¥27.97 Million | CN¥60.00 Million | CN¥27.97 Million | — |